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Abstract
Background: This study aims to better define prognostic factors for patients with metastatic urothelial carcinoma
(mUC), and to identify patients who will benefit from first-line cisplatin-based chemotherapy. We test the hypothesis
that early objective response (EOR), defined as the occurrence of an objective response following 2 or 3 courses of
chemotherapy, could be a prognostic factor for overall survival (OS) and thus be used to guide treatment decisions.
Data from 113 patients with evaluable mUC receiving first-line cisplatin-based treatment between January 2004 and
December 2006 was collected retrospectively from prospectively-maintained databases across seven French cancer
centers. Clinical factors potentially associated with survival and EOR were analyzed in univariate and multivariate
analysis.
Results: One hundred three patient records were complete and available for inclusion in the multivariate model.
Four factors were independently associated with OS: Performance status 1 and 2 (HR 2.3 [95 % CI 1.3–3.9], p = 0.002;
HR 3.4 [95 % CI 1.6–7.2], p = 0.001 respectively); presence of visceral metastases (HR 2.2 [95 % CI 1.3–3.9], p = 0.004);
abnormal hemoglobin levels (HR 1.7 [95 % CI 1.01–2.8], p = 0.045); disease progression (HR 10.1 [95 % CI 4.2–24.1],
p < 0.001).
Conclusions: This study confirms the prognostic factors previously reported in first-line chemotherapy for mUC.
However, we failed to demonstrate that EOR was an independent predictive factor of OS. Nevertheless, an early
response evaluation is recommended since early progression is an important parameter that can be used to
decide whether treatment should be interrupted and changed for alternative strategies integrating the concept
of personalized medicine or new immune therapies.
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Background
Bladder cancer is the second leading cause of death in
urologic cancer in men and women [1]. Cisplatin-based
chemotherapy represents the standard treatment for
metastatic urothelial carcinoma (mUC) when patients
are eligible. Median overall survival (OS) after this regi-
men has remained relatively stable since the last two
decades at around 14–15 months [2, 3]. A better safety
profile is obtained when a combination of gemcitabine
and cisplatin (G-C) [4], is used as compared to the
methotrexate-vinblastine-adriamycine-cisplatin regimen
(M-VAC). Vinflunine is the only second-line treatment
approved at present, with a small benefit on survival
when adjusted on prognostic factors [5] and a restricted
availability due to financial reasons. Currently, no other
standard treatments are approved after failure of a
cisplatin-based regimen, including targeted or immune
therapies [6], however recent studies have shown prom-
ising results using well tolerated drugs with prolonged
clinical benefit [7, 8]. Because of the relatively high tox-
icity of this first-line regimen, it appears crucial to
better identify patients who will benefit the most from
this treatment. In practice, if a patient does not respond
at the first evaluation after 2 or 3 courses, research is
needed to answer the question of whether this regimen
should be continued or not.
Prognostic factors of survival and predictive factors of
response are necessary to help physicians make clinical
decisions. Previous studies have reported prognostic fac-
tors of survival based on standard first-line chemother-
apies with ECOG Performance Status (PS) and visceral
metastasis independently associated with OS in most
studies [2, 3, 9, 10]. PS and visceral metastasis are defined
as the main independent predictive factors of response to
cisplatin-based chemotherapy in mUC [2, 10, 11]. Further-
more, Sengelov et al. [11] proposed to identify the impact
of objective response (WHO criteria) on survival, analyz-
ing data from 119 evaluable patients (4 consecutive phase
II studies performed between 87 and 97) with locally-
advanced or mUC at diagnosis, as well as with metastatic
or regional relapse after a local treatment. Median survival
was 12.4 months in responder patients and 6.3 months in
non-responder patients. Response to chemotherapy was
included in the multivariate analysis and was found as the
strongest prognostic factor for survival. To our knowledge
this is the only study that has identified objective response
as an independent prognostic factor. We thus aimed to
focus on early objective response (EOR), defined as the oc-
currence of an objective response following 2 or 3 courses
of cisplatin-based chemotherapy, hypothesizing that EOR
could independently impact on OS. This data could be
useful to inform treatment decisions, for example switch-
ing protocols for patients with stable disease (SD) and
avoiding serious side effects of these treatments that could
potentially be inefficient. This treatment strategy could
accelerate inclusions in subsequent clinical trials guided
by personalized medicine, or new immunotherapies.
Results
Population
Medical records for 113 patients with a metastatic urothe-
lial cancer (mUC) were retrieved from prospectively-
maintained institutional databases (Table 1). Thirty patients
received their first course of chemotherapy in 2004, 40 in
2005 and 43 in 2006. The female/male sex ratio was 1/4.2
and median age at the first course was 63.7 years (range
33.7–79.6). A majority (85 %) of patients had PS of 0–1.
Forty-one patients (36.3 %) relapsed following treatment of
a localized tumor (with a median time to relapse of 9.47
months) and 72 (63.7 %) had metastatic disease at the time
of diagnosis. Eighty-six (76.1 %) patients received a
combination of G-C, 12 (10.6 %) an M-VAC regimen,
and 15 (13.3 %) had a switch from cisplatin to carbopla-
tin during therapy (in the subset G-C regimen only),
after a minimum of 3 cycles of cisplatinum-based regi-
men for all patients.
Early objective response (EOR)
All patients were available for response evaluation follow-
ing 2 or 3 cycles. Three patients achieved CR (following 3
cycles), 61 patients achieved PR (23 after 2 cycles and 38
after 3), giving 64 patients with an EOR and an EOR rate
of 56.6 %. Thirty-eight (33.6 %) stable disease (SD) and 11
(9.7 %) progressive disease (PD) were reported after 2 or 3
cycles of first line chemotherapy.
Toxicities, further treatments and survival
Toxicities are reported in Table 2. In terms of Grade 3/4
severe toxicities, neutropenia was the most frequent,
followed by thrombopenia and infection. Fifty-one (45.1 %)
patients received treatments following and/or completing
this first-line chemotherapy with 5 receiving concomitant
radio-chemotherapy (no radiotherapy alone) and 46 receiv-
ing subsequent chemotherapy.
The median follow up was 47.1 months [95 % CI:
41.4–54.3]. At the time of analysis 19 (16.8 %) patients
were alive, 85 (75.2 %) had died from their disease, 1
(0.9 %) from treatment-related toxicity and 1 from an-
other cause. Seven (6.2 %) patients were lost to follow-
up. The median overall survival was 16.43 months [95 %
CI: 13.0–18.6]. Survival according to whether the pa-
tients achieved an EOR or not are presented in Figs. 1
and 2. We did not find any significant differences in
overall survival according to response (responder n = 64
and non-responder n = 49): median survival of 16.0
months [95 % CI: 12.9–24.6] and 13.2 months [95 % CI:
9.1–18.6] respectively (P = 0.16).
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Prognostic analysis: univariate and multivariate analysis
(Table 3)
Five parameters were found to be related to OS fol-
lowing univariate analysis: higher PS (P = 0.001), more
metastatic sites (P < 0.001), presence of visceral metasta-
ses (P < 0.001), abnormal hemoglobin level (P = 0.029),
and the occurrence of an EOR (P = 0.002).
Ten patients (8.8 %) were excluded from the multivari-
ate analysis due to incomplete hemoglobin level data. Four
factors were independently associated with poorer OS: PS
1 (HR 2.3 [95 % CI 1.3–3.9], p = 0.002) and PS 2 or 3 (HR
3.4 [95 % CI 1.6–7.2], P = 0.001), presence of visceral me-
tastases (HR 2.2 [95 % CI 1.3–3.9], P = 0.004), abnormal
level of hemoglobin (HR 1.7 [95 % CI 1.01–2.8], P = 0.045),
and progressive disease, (HR 10.1 [95 % CI 4.2–24.1],
P < 0.001). The hazard ratio for EOR (CR + PR) was
1.45 [95 % CI 0.9–2.4], P = 0.16.
Discussion
This multicenter retrospective study identified four inde-
pendent prognostic factors of poorer overall survival: high
Table 1 Population characteristics for patients with metastatic
urothelial carcinoma treated by first-line cisplatin-based
chemotherapy (n = 113)
Characteristics n (%)
Male/female 91 (80.5) / 22 (19.5)
Age in years, (median [range]) 63.24 [33.7–79.7]
Performance Status
0 46 (40.7)
1 50 (44.2)
2–3 17 (15.0)
Metastatic relapse
Yes 41 (36.3)
No 72 (63.7)
Number of metastatic sites
1 39 (34.5)
2 51 (45.1)
3 17 (15)
>3 6 (5.3)
Metastatic sites (non-exclusive)
Lymph node under the diaphragm 84 (74.3)
Lymph node above the diaphragm 20 (17.7)
Bone 36 (31.9)
Lung 44 (38.9)
Liver 23 (20.4)
Other 8 (7.1)
Visceral metastases (lung – liver – bone) 77 (68.1)
Haemoglobin level
>11g/dl 61 (54)
<11g/dl 42 (37.2)
Unknown 10 (8.8)
Creatinine clearance
Normal 76 (67.3)
Abnormal 20 (17.7)
Unknown 17 (15)
AP
Normal 48 (42.5)
Abnormal 32 (28.3)
Unknown 33 (29.2)
LDH
Normal 36 (31.9)
Abnormal 24 (21.2)
Unknown 53 (46.9)
Chemotherapy
G-C 86 (76.1)
M-VAC 12 (10.6)
G-C switched to G-Carboplatin 15 (13.3)
Table 1 Population characteristics for patients with metastatic
urothelial carcinoma treated by first-line cisplatin-based
chemotherapy (n = 113) (Continued)
Response following 2 or 3 cycles
CR 3 (2.7)
PR 61 (54)
SD 38 (33.6)
PD 11 (9.7)
EOR 64 (56.7)
Subsequent treatmentsa 51 (45.1)
Chemotherapy 46 (40.7)
Chemoradiotherapy 5 (4.4)
Radiotherapy 0
LDH: lactate deshydrogenase ; AP: alkaline phosphatase ; G-C: gemcitabine –
ciplatin ; M-VAC: methotrexate – vinblastine – adriamycine – cisplatin ;
G: gemcitabine ; CR: complete response. PR: partial response SD: stable disease.
PD: progressive disease. EOR: early objective response (RECIST criteria v.1)
aunknown: 20 (25 %)
Table 2 Toxicity (NCI CTCAE v.3)
Grades n (%)
1 2 3 4
Fatigue 43 26 12 0
Nausea/vomiting 27 32 8 0
Infection 2 14 12 2
Anaemia 34 33 11 0
Thrombopenia 18 13 13 3
Leucopoenia 9 12 18 11
Renal 21 11 2 0
Roubaud et al. Journal of Negative Results in BioMedicine  (2015) 14:18 Page 3 of 7
PS, presence of visceral metastases, abnormal levels of
hemoglobin and early PD. All patients had metastatic
disease (not locally advanced) and were initially treated
with a cisplatin-based regimen corresponding to an homo-
geneous population. Moreover, it represents a good reflec-
tion of practice in France, with a majority of patients
being treated with a G-C regimen instead of M-VAC as
first-line chemotherapy for mUC. Patient characteristics
and median OS are similar to other studies [4, 9–15].
Toxicity was comparable to that reported in the phase
III study by von der Maase et al. [4].
PS and visceral metastases are well known as inde-
pendent prognostic factors of survival in mUC and have
been previously reported in at least 10 different studies
[2, 3, 9–13, 16–18]. Early PD was an independent prog-
nostic factor of survival and EOR was not. Our data did
not confirm that previously reported by Sengelov et al.
[11] regarding the impact of objective response on sur-
vival. This could be explained by several differences such
as period of treatment and care management (between
1987 and 1997 vs. between 2004 and 2006), assessment of
objective response (WHO vs. RECIST criteria), or time of
assessment (not specifically following 2 or 3 cycles, in the
first step of treatment). Unlike Sengelov et al. we preferred
to maintain three groups in our analysis (EOR, SD and
PD), considering the absence of significant differences
in survival between the responder population and those
with stable disease (P = 0.16 in multivariate analysis
and in Fig. 1). Survival curves have also been presented
by Sengelov et al. [11] and seem to show a comparable
survival between SD and PR (median OS not shown by
the authors). To go further in the comparison, in Fig. 2,
using the same presentation as Sengelov et al. with OS
according to responder versus non responder patients,
we did not find any significant differences between the
two groups (Fig. 2). Nevertheless, this methodology of
separation of categories previously reported could be
discussed especially for SD and PR populations, which
seem to be comparable across the two studies.
Our report contains some biases, which are inherent
to any retrospective study over a long period. First, the
chemotherapy protocol is not homogeneous, as different
regimens were used including a switch from a cisplatin- to
carboplatin-based regimen for 13.3 % of patients during
therapy. This regimen is used for the “unfit population”
for a cisplatin regimen and median overall survival re-
ported is approximately 10 months, which is less than
other reports using cisplatin-based regimen [14]. However
in these subsets, no differences were reported between
GC, M-VAC and GC switched to G-Carboplatin in uni-
variate analysis on survival (P = 0.18). Second, survival
data could be influenced by subsequent treatments, such
as concomitant chemo-radiotherapy or subsequent che-
motherapies, which were not tested in our analysis due to
their dependence on the results to the chemotherapy.
Third, we excluded 10 (8.8 %) observations, leaving 103
patients for multivariate analysis: this relatively low num-
ber could have contributed to a lower statistic power as
compared with previous reports e.g. 119 patients in study
reported by Sengelov et al. [11].
We did not confirm our primary hypothesis in this
study, even if we found that early progression has an
impact on survival for this population. EOR could re-
main a relevant predictive factor of survival since the
other well-known parameters were found to be inde-
pendently associated with OS, and this difference could
be explained by a lack of statistical power. This data
does not indicate that changes in treatment strategies
are required, but it could be useful to predict early pro-
gression following standard first-line chemotherapy, and
avoid potential side effects from this treatment.
The obvious question now is how to treat patients who
will not benefit from cisplatin-based regimens? Previous
studies have proposed some sequential chemotherapy in
bladder cancer with limited effects reserved to highly se-
lected populations (good performance status and limited
Fig. 1 Survival curves according to early objective response (EOR),
stable disease (SD) and progressive disease (PD). EOR (blue): early
objective response (complete response + partial response; RECIST
criteria v.1) SD (red): stable disease, PD (green) progressive disease
Fig. 2 Survival curves according to occurrence or absence of early
objective response (EOR). EOR (blue): early objective response (complete
response + partial response; RECIST criteria v.1); absence of EOR (red):
stable disease + progressive disease
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metastatic spread) as reported by Siefker Radtke et al. [15].
New drugs and progress in tumoral biology understanding
could provide alternative treatments [19, 20]. Recent phase
II trials using everolimus or temsirolimus [21, 22] and
nanoparticle albumin-bound paclitaxel [23] achieved clin-
ical benefit and durable response. Similarly, immune ther-
apies targeting PD-1 and PD L-1 have shown noteworthy
results in terms of objective response rate and response
duration in phase I recently reported [7, 8]. Thus, it is im-
portant to detect the absence of efficacy of a toxic first-line
regimen early, to enable a change for a new treatment ei-
ther in the era of immunotherapy or potentially integrated
in a personalized medicine approach according to well-
known biomarkers in urothelial carcinoma [24]. An in-
terim analysis of the prospective trial MOSCATO 01 has
shown feasibility in daily practice of such an approach [25].
Conclusions
In conclusion, this multicenter French retrospective
study performed on a population of patients treated with
cisplatin-based regimen for a mUC, does not support
the hypothesis that EOR could be associated with a bet-
ter survival. Nevertheless, an early response evaluation
after 2 or 3 courses of chemotherapy is recommended
Table 3 Univariate and multivariate analysis of prognostic factors of overall survival for patients with metastatic urothelial carcinoma
treated by first-line cisplatin-based chemotherapy (n = 103)
Log rank test Univariate analysis Multivariate analysis
HR [95 % CI] p de wald HR [95 % CI] p de wald
Sex 0.88
Male 0.96 [0.57–1.6] 0.88
Female 1
Age 0.34
<64 years 1
> = 64 years 0.82 [0.54–1.24] 0.34
PS <0.001
PS 0 1 1
PS 1 2.11 [1.31–3.40] 0.002 2.3 [1.3–3.9] 0.002
PS 2 or 3 4.98 [2.61–9.49] <0.001 3.4 [1.6–7.2] 0.001
Hb level (cut-off: 11g/dl) 0.03
Normal 1 1
Abnormal 1.65 [1.05–2.6] 0.029 1.7 [1.01–2.8] 0.045
Metastatic relapse 0.90
No 1
Yes 0.97 [0.62–1.51]0.90
N metastatic site <0.001
1 1 excluded p = 0.76
2 1.63 [0.99–2.70] 0.054
≥3 2.87 [1.60–5.2] <0.001
Visceral metastases <0.001
No 1 1
Yes 2.29 [1.4–3.7] 0.001 2.2 [1.3–3.9] 0.004
Chemotherapy regimen 0.18
G-C 1
M-VAC 0.60 [0.28–1.27] 0.18
G-C and G-carboplatin 1.40 [0.77–2.55] 0.27
Response to treatment 0.002
SD 1 1
EOR (CR + PR) 0.93 [0.6–1.5] 0.75 1.45 [0.9–2.4] 0.16
PD 3.2 [1.5–6.5] 0.002 10.1 [4.2–24.1] 0.000
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because early progression is an independent prognostic
factor of poorer survival, indicating that the treatment
should be stopped or changed earlier, favoring new
strategies based on personalized medicine or immune
therapies.
Methods
This retrospective multicenter study involving seven
French medical centers was approved by the French
data protection authority (Commission Nationale Infor-
matique et Liberté, CNIL) and was supported by the
French cooperative GU tumors group (GETUG). Ac-
cording to French data protection authority rules, a
patient informed consent was not required, however, a
document of information was provided to patients who
were alive at the time of the analysis. Data was
collected from the medical files of patients including
patient characteristics, survival data and clinical param-
eters previously described as independent prognostic
and/or predictive factors (sex; age (<64/> = 64y); PS
(0,1,2 or 3); Hemoglobin level (normal/abnormal ≤11g/dl);
metastatic relapse (yes/no); number of metastatic sites
(1,2,> = 3); visceral metastases (defined as presence of
metastases in the liver and/or lung and/or bone);
chemotherapy regimen (G-C, M-VAC, G-C and G-
carboplatin), all patients had cisplatin based regimen
prior assessment of response following 2 or 3 cycles.
An EOR was defined as the occurrence of partial
response (PR) or complete response (CR) obtained fol-
lowing 2 or 3 courses of chemotherapy, according to
RECIST criteria 2000 [16]. Stable disease was used as a
reference category comparing SD and EOR. Only pa-
tients with metastatic (all T, all N and M1 according to
the TNM classification 2002) urothelial carcinoma were
included. All patients had not received chemotherapy
prior to being treated with either G-C or M-VAC and
treatment started between January 1st 2004 and December
31st 2006. Toxicity data was collected in the clinical
chart and classified retrospectively according to the
NCI CTCAE v.3 scale. Statistical analyses were per-
formed with SPSS v.17 software (Cary, NJ). Survival
probability was calculated by the Kaplan-Meier method,
and defined as the time from the first day of the initial
course of chemotherapy to the date of last follow-up or
death. Median follow-up was calculated by the reverse
Kaplan-Meier method and is reported with 95 % confi-
dence interval (CI). Univariate analyses of prognostic
factors and EOR was performed using log rank tests
and all variables significant at P < 0.05 were included in
the multivariate analysis. After a test of proportional
hazard assumptions, the multivariate model used a
stepwise descending method and P < 0.05 was consid-
ered significant.
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